![](/img/cover-not-exists.png)
Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial
Elez, E., Kocakova, I., Hohler, T., Martens, U. M., Bokemeyer, C., Van Cutsem, E., Melichar, B., Smakal, M., Cs szi, T., Topuzov, E., Orlova, R., Tjulandin, S., Rivera, F., Straub, J., Bruns, R., QuarVolume:
26
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdu474
Date:
January, 2015
File:
PDF, 422 KB
english, 2015